News & Press Releases

Boston Business Journal connected with John Rudy to discuss private investment in public equity (PIPE) financings for an article that outlines their purpose, what entering a PIPE could signify for companies, and how they might be particularly useful for SPAC mergers.

CAMBRIDGE, MA—Mintz will host its fourth annual Energy Transition Summit: Shaping Our Energy Future – The Path Forward on October 27. The Summit will bring together nearly 150 leaders from across the public and private sectors for a day focused on the technologies driving the energy transition and the legal and financial structures supporting their growth. Held at The Engine, MIT’s accelerator for breakthrough technologies, the Summit will kick off Tough Tech Week 2025, a multi-day celebration of innovation in Cambridge’s tech ecosystem.

Mintz advised the underwriters in connection with a $345 million public offering by uniQure of 6,736,841 ordinary shares (which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares) at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 ordinary shares at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to uniQure from this offering were approximately $345 million before deducting underwriting discounts and commissions and other offering expenses. 

Fiduciary News quoted Of Counsel Michelle Capezza in an article about the rise of AI advice tools in retirement plan platforms. While these tools may offer efficient, data-driven, and personalized advice, they also present risks such as data breaches, opaque algorithms, and biased results.

Mintz advised Rendezvous Robotics, a space infrastructure company pioneering modular, autonomous in-orbit assembly, on the close of its $3 million Pre-Seed round and its public emergence from stealth.

PharmaVoice quoted Associate Mitchell Clough in an article about a recent string of court losses for pharmaceutical companies in cases challenging drug price negotiations created under the Inflation Reduction Act, which could make their way to the Supreme Court docket soon.